Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-09
2011-08-09
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S594000
Reexamination Certificate
active
07994163
ABSTRACT:
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.
REFERENCES:
patent: 4265890 (1981-05-01), Holden et al.
patent: 4985352 (1991-01-01), Julius et al.
patent: 5639748 (1997-06-01), DeMarinis et al.
patent: 5698766 (1997-12-01), Julius et al.
patent: 0285 287 (1988-10-01), None
patent: 1213017 (2002-06-01), None
patent: WO 93/03015 (1993-02-01), None
patent: WO 93/04686 (1993-03-01), None
patent: WO 93/04866 (1993-03-01), None
patent: WO 02/074746 (2002-09-01), None
patent: WO/02/074746 (2002-09-01), None
patent: WO 03 006466 (2003-01-01), None
patent: WO 03/045940 (2003-06-01), None
patent: WO 2003/086306 (2003-10-01), None
patent: WO 2005/003096 (2005-01-01), None
patent: WO 2005/019179 (2005-03-01), None
patent: WO 2005/019180 (2005-03-01), None
patent: WO 2005/042490 (2005-05-01), None
patent: WO 2005/042491 (2005-05-01), None
patent: WO 2005/082859 (2005-09-01), None
patent: WO 2006/069363 (2006-06-01), None
patent: WO 2006/071740 (2006-07-01), None
Vikers et al.,Psycholpharmacology, 167: 274-280 (2003).
Tecott et al.,Nature, 374: 542-546 (1995).
Martin et al.,Pharmacol. Biochem. Behav., 71: 615 (2002).
Chou-Green et al.,Physiology&Behavior, 78: 641-649 (2003).
Leysen et al.,Trends in Drug Research II, 29: 49-61 (1998).
Frank et al.,Neuropsychopharmacology27: 869-873 (2002).
Upton et al.,Eur. J. Pharmacol., 359:33 (1998).
Fitzgerald, Ennis,Annual Reports in Medicinal Chemistry, 37: 21-30 (2002).
Nelson et al.,Naunyn-Schmiedeberg's Arch. Pharm., 359: 1-6 (1999).
V. Setola et al.,Mol. Pharmacology, 63: 1223-1229 (2003).
Frishman, Kotob,Journal of Clinical Pharmacology, 39: 7-16 (1999).
Seeman, Van Tol,Trends in Pharmacological Sciences, 15: 264-270 (1994).
Data Base Registry: XP002419374, Sep. 30, 2005.
Database Registry: XP002419375, Sep. 30, 2005.
Database Registry: XP002419376, Sep. 30, 2005.
Database Registry: XP002419377, Sep. 30, 2005.
Allen John Gordon
Briner Karin
Galka Christopher Stanley
Hoying Richard Charles
Martinez-Grau Maria Angeles
Coleman Brenda
Eli Lilly and Company
Tucker R. Craig
LandOfFree
6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671575